Efficacy and safety of esaxerenone in hypertensive patients with chronic kidney disease, with or without type 2 diabetes mellitus: a pooled analysis of five clinical studies.

ABSTRACT: Effective management of blood pressure (BP) and albuminuria are crucial for suppressing chronic kidney disease (CKD) progression and cardiovascular risks in hypertension. This pooled analysis evaluated the antihypertensive effects, organ-protective effects, and safety of esaxerenone in hypertensive patients with CKD by integrating five clinical studies of esaxerenone. Patients were divided based on type 2 diabetes mellitus (T2DM) status (with or without T2DM) and creatinine-based estimated glomerular filtration rate (eGFR_creat) (30 to <60 and ≥60 mL/min/1.73 m²). Significant changes in morning home BP from baseline at Week 12 were observed in the overall population (mean change -12.8/ - 5.4 mmHg), T2DM subgroups ( - 12.2/ - 4.5 and -14.5/ - 7.8 mmHg), and eGFR_cre

SUBMITTER: Uchida HA 

PROVIDER: S-EPMC12411229 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature